NEW YORK (GenomeWeb) – Biocept said today that it has begun a clinical research collaboration with the University of Texas Southwestern Medical Center focused on non-small cell lung cancer.

The company will work with a team led by UT Southwestern researcher Saad Khan to evaluate its Target Selector platform for rapid detection of ALK mutations in patients with NSCLC. Tests will be performed both at baseline and longitudinally to measure treatment response and early signs of resistance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.